Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.
Upadhyay R, Boiarsky JA, Pantsulaia G, Svensson-Arvelund J, Lin MJ, Wroblewska A, Bhalla S, Scholler N, Bot A, Rossi JM, Sadek N, Parekh S, Lagana A, Baccarini A, Merad M, Brown BD, Brody JD. Upadhyay R, et al. Among authors: scholler n. Cancer Discov. 2021 Mar;11(3):599-613. doi: 10.1158/2159-8290.CD-20-0756. Epub 2020 Dec 17. Cancer Discov. 2021. PMID: 33334730 Free PMC article.
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, Chang EC, Neelapu SS, Miklos DB, Jacobson CA, Lekakis LJ, Lin Y, Ghobadi A, Kim JJ, Chou J, Plaks V, Wang Z, Xue A, Mattie M, Rossi JM, Bot A, Galon J. Scholler N, et al. Nat Med. 2022 Sep;28(9):1872-1882. doi: 10.1038/s41591-022-01916-x. Epub 2022 Aug 29. Nat Med. 2022. PMID: 36038629 Free PMC article.
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, Hansen B, Stroncek DF, Rosenberg SA, Gress RE, Kochenderfer JN. Brudno JN, et al. Among authors: scholler n. Nat Med. 2020 Feb;26(2):270-280. doi: 10.1038/s41591-019-0737-3. Epub 2020 Jan 20. Nat Med. 2020. PMID: 31959992 Free PMC article. Clinical Trial.
Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies.
Ghobadi A, Landmann JH, Carter A, Cooper ML, Selli ME, Chang J, Baker M, Miller CA, Ferraro F, Chen DY, Smith AM, LaValle TA, Duncavage EJ, Chou J, Tam V, Benoun JM, Nater J, Scholler N, Milletti F, Vezan R, Bot A, Rossi JM, Singh N. Ghobadi A, et al. Among authors: scholler n. Blood Adv. 2022 Oct 25;6(20):5634-5640. doi: 10.1182/bloodadvances.2022007705. Blood Adv. 2022. PMID: 35858291 Free PMC article. No abstract available.
Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, Hansen B, Stroncek DF, Rosenberg SA, Gress RE, Kochenderfer JN. Brudno JN, et al. Among authors: scholler n. Nat Med. 2020 May;26(5):803. doi: 10.1038/s41591-020-0864-x. Nat Med. 2020. PMID: 32291416 Free PMC article.
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD Jr, Scholler J, Scholler N, Bonneau R, June CH. Guedan S, et al. Among authors: scholler j, scholler n. Blood. 2014 Aug 14;124(7):1070-80. doi: 10.1182/blood-2013-10-535245. Epub 2014 Jul 1. Blood. 2014. PMID: 24986688 Free PMC article.
60 results